GoemansNM, TuliniusM, van den HauweM, KroksmarkAK, BuyseG, WilsonRJ, van DeutekomJC, de KimpeSJ, LourbakosA, and CampionG. (2016). Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: results from an open-label extension study. PLoS One, 11:e0161955.
MendellJR, Rodino-KlapacLR, SahenkZ, RoushK, BirdL, LowesLP, AlfanoL, GomezAM, LewisS, et al; Eteplirsen Study Group. (2013). Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol, 74:637–647.
MendellJR, GoemansN, LowesLP, AlfanoLN, BerryK, ShaoJ, KayeEM, and MercuriE; Eteplirsen Study Group and Telethon Foundation DMD Italian Network. 2016). Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol, 79:257–271.
StraubV, BalabanovP, BushbyK, EnsiniM, GoemansN, De LucaA, PeredaA, HemmingsR, CampionG, et al. (2016). Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol, 15:882–890.
